Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What do you mean by ‘ours’?
I think 2025 is going to be our year!
Hi Geo. I hope you're doing well.
I havent been on this site since the ending fall out w titan. I guess our old board is gone. Nothing like sensorship and silencing their investors.. sickening. I'm really only able to reply because of an old message from you that was in my inbox here. I was just wondering if you guys are still posting anywhere about titan or whatever the loser name is now? Or, anything new.. lawsuits to join..? If you're interested, feel free to email me direct at magnetics101@yahoo.com . Thanks and take care.
Déjà vu… Dilute dilute dilute
BelizeMe
RBOT did a 1-30 RS last year which landed the stock at around $5/share
HOWEVER unlike POS Titan RBOT has steadily climbed from there to now approaching $20/ share!
I'm waiting for Giovinazzo and Steiner to be of some use!
But I don't have much hope
What are we looking at here buddy? Thanks in advance for any information.
It’s a shame most of us got totally whipped out. Oh well. Win some. Loose some.
In other single port robotic news RBOT did a 1 for 30 RS a number of months ago….
The RS brought it to around $5 however unlike TMDI the stock stayed stable and has continued to rise to over $8 today.
Worth watching IMO
1 for 25 reverse split
TMDIF: effective Oct. 16,2024: Titan Medical has completed an amalgamation involving Conavi Medical Inc. Titan Medical and a wholly-owned subsidiary of the Company, 1000824255 Ontario Inc., which resulted in the reverse takeover of the Company by Conavi. Following completion of the Amalgamation, the Company has been renamed Conavi Medical Corp. Immediately prior to the closing of the Amalgamation, the Shares of the Company were consolidated on a 1-for-25 basis.
https://otce.finra.org/otce/dailyList?viewType=Deletions
I think voting was done on Dominion machines.
Will do brutha! I lost on Verb too. Cuin2 is/was the biggest f’n hack pumper!
F him and his Blue Ocean Strategy!
Once again Titan shareholders give management what they want….
Never worked a single time before….
Congratulations on locking in your losses people….
Thanks for your message Geo! I also got burned on VERB.. Please try to reach out to me again if you hear anything new. I've never been to stock twits but, maybe I should.. I thought that was where all the smart titan investors went. To Scoopsville...
Mag, we may go after’em. If you have an account on StockTwits, go read through some of our latest posts. A few of us are trying to rally the troops. This is what gives us a glimmer of hope…
https://www.reuters.com/legal/judge-rules-that-jj-owes-auris-1-bln-related-2019-robot-deal-2024-09-04/
I can't believe the same folks are still hanging in to titan. If you haven't sold out... It's over... Time to move on to another company. Check out Monogram robotics. Ortho robotics is where the market is heading...
Agree with you. Worst financial mistake of a lifetime. I regret hearing about this company and will never invest in a penny again.
Checking in probably one last time here as I've lost over 150k on this.. worst experience of my life.. even more painful that it went on for 12 plus years of pain. I'm writing here one last time hoping that no one is voting yes on this.. and if you do you might as well vote for Kamala as well. After losing 150k + and still having all those shares that have been reverse split who knows how many times I'm left with a total of just 1,500 or so in stock.. a yes vote will bring even less. Only one getting paid will be the company directors on both side and lawyers.. please vote no and shut these scammers down! And I won't be attending the conference call because there's nothing to hear. It's been fun communicating with some of you over the years here. Big lesson learned here. And that this place is full of evil people trying to scam all day everyday
Can you please explain why you are recommending a no vote? I don’t think this company as it stands will be able to continue if they don’t do something. but in all honesty I haven’t read the circular yet so I don’t really have an educated opinion as of today. But I appreciate any info you are willing to provide. Thanks in advance and good luck. We may need it. Lol.
No R&D……where did all those MILLIONS go since 12/31/23?????
VOTE NO!!!!!!!!
Titan Medical Reports Operating and Financial Results for the Second Quarter 2024
Titan Medical Inc.
Thu, Aug 15, 2024, 11:32 AM CDT6 min read\
TORONTO, Ontario, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the three and six months ended June 30, 2024.
Recent Activities in Q2 2024:
On May 29, 2024, the Company announced an amendment to the timeframe under which certain closing conditions must be met in the amalgamation agreement dated March 17, 2024 with Conavi Medical Inc. (“Conavi”), 1000824255 Ontario Inc. (a wholly-owned subsidiary of Titan) (the “Amalgamation Agreement”).
On July 5, 2024, the Company announced the second amendment to the timeframe under which certain conditions must be met in the Amalgamation Agreement and announced the Company was seeking an additional extension with the Toronto Stock Exchange (“TSX”) to hold its Annual General and Special Meeting of Shareholders (the “Titan AGM”) on or before September 30, 2024.
On August 14, 2024, the Company announced the third amendment to alter certain closing conditions that must be met in the Amalgamation Agreement.
extending the Outside Date (as such term is defined in the Amalgamation Agreement) for completion of the Proposed Transaction to October 10, 2024;
extending the date by which the Concurrent Financing (as such term is defined in the Amalgamation Agreement) must be committed to September 3, 2024;
reducing the minimum aggregate size of the Concurrent Financing (as such term is defined in the Amalgamation Agreement) from $15 million to $7.5 million;
extending the date by which Conavi financial statements must be completed to August 23, 2024;
reducing the minimum net cash Titan must have at the Effective Time (as such term is defined in this Amalgamation Agreement) from US$5 million to US$2 million;
extending the targeted date by which the information circular for the Titan AGM must be mailed to shareholders to September 3, 2024;
extending the targeted date by which the Titan AGM must be held to September 30, 2024;
extending the targeted date by which the information circular for the Conavi annual general meeting must be mailed to shareholders to September 3, 2024; and
extending the targeted date by which the Conavi annual general meeting must be held to September 30, 2024.
Financial Highlights:
As of June 30, 2024, Titan had cash of $3.9 million, compared to $7.5 million as at December 31, 2023. Working capital was $3.3 million as of June 30, 2024, compared to $5.5 million as at December 31, 2023.
Research and development (“R&D”) expenses were nil for the three months ended June 30, 2024 compared to $0.4 million for the three months ended June 30, 2023. R&D expenses were recovery of $0.1 million for the six months ended June 30, 2024 compared to $0.8 million for the six months ended June 30, 2023.
In the three and six months ended June 30, 2023, the Company implemented cost-cutting measures that significantly reduced R&D expenses. In the six months ended June 30, 2024, R&D expense recovery of $0.1 million is attributed to cancellation of stock options and restricted share units related to R&D personnel.
General and administrative (“G&A”) expenses were $1.1 million and $2.0 million for the three and six months ended June 30, 2024 compared to $4.3 million and $6.6 million for the comparative periods ended June 30, 2023. The decrease in G&A expenses in the current period is related to the cost-cutting measures implemented in Q2, 2023. In 2023, G&A expenses included severance charges of $1.4M, transaction costs of $1.5M, and increased stock-based compensation, offset by reduction in costs due to cost-cutting measures.
The Company’s interim consolidated financial statements and management discussions and analysis for the period ended June 30, 2024 are available at www.sedarplus.ca. The Company’s condensed interim consolidated financial statements have been prepared by management and reviewed by the Company’s auditors.
About Titan Medical
Titan Medical Inc. (TSX: TMD; OTC: TMDIF) is a medical technology company incorporated under the Business Corporations Act (Ontario) and headquartered in Toronto, Ontario, has developed an expansive patent portfolio related to the enhancement of robotic assisted surgery (RAS), including through a single access point, and is currently focused on evaluating new opportunities to further develop and license its intellectual property while pursuing the completion of its agreed upon Transaction with Conavi Medical Inc.
Cautionary Statement Regarding Forward-Looking Information
This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Titan’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: Titan evaluating new opportunities to further develop and license its intellectual property, the payment of future settlement amounts, the delivery of materials to Titan, and the completion of the merger with Conavi.
These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Titan’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Titan’s ability to retain key personnel; its ability to execute on its business plans and strategies; its ability to continue to license some or all its intellectual property to third parties and receive any material consideration and other factors listed in the “Risk Factors” section of Titan’s Annual Information Form for the fiscal year ended December 31, 2023 (which may be viewed at www.sedarplus.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Titan has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Titan cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Titan expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.
Contact
Chien Huang
Chief Financial Officer
investors@titanmedicalinc.com
Vote NO to reverse takeover.
Why vote yes and lock in our 99.9% loss?
Upside? What upside? You realize they’ve robbed stakeholders right? They’ve spent hundreds of millions on a single-port robot and they stopped development. They pissed away their entire IP portfolio for pennies and no one even knows where the device is at this point.
Happy Sunday. I'm a weekend warrior that recently discovered the Investors hub community. Been following the developments with Titan Medical Inc. (TMD) licensing deals with others for near future royalties, and also the pending Conavi Medical reverse buyout / merger. As per the info I have read in the Links below, I gather that they are in talks to Delist from the TSX: TMD; OTC: TMDIF),to then move to the TSXV after the deal hopefully gets done. I believe there is good upside with the TMD company either way. Therefore, can anyone that is savvy with this type of company reverse buyout/merger restructuring terms etc., please advise if TMD will want to, or will have to Change their Trading Symbol for the transition to the TSXV ? Thanks, appreciate any thoughts and/or comments for insight on what we may potentially be able to anticipate.
https://ih.advfn.com/stock-market/USOTC/vivos-qb-RDGL/stock-news/94191743/form-1-a-a-offering-statement-regulation-a-a
https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:d031aa10-2849-4915-827d-efa78f75b532
https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:a181e427-d506-468b-8fbf-093ff89ad5a6
Followers
|
490
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
140523
|
Created
|
10/18/10
|
Type
|
Free
|
Moderators |
Titan Medical
January 10, 2022 Titan Medical Corporate Presentation
https://d1io3yog0oux5.cloudfront.net/_101e2d94c73b26bc133246c537736f29/titanmedicalinc/db/1086/9873/pdf/Titan+-+IR+Presentation+-+Q1+2022+FINAL.pdf
*200+ patents issued or pending
Surgeon Feedback From Initial Clinical Testing:
Ricardo Estape, M.D., a robotic gynecologic oncology surgeon from South Miami Gynecology Oncology Group who specializes in robotic single port surgeries, said, “The SPORT Surgical System performed beyond my expectations and I was able to complete a variety of critical surgical tasks with the necessary dexterity and precision through a single incision. The robotic instruments provided the necessary articulation, range of motion and rigidity along with 3D high-definition video on the flat panel monitor that allowed me to complete the surgery in a comfortable posture. This could be a game changer in gynecological surgery.” SEE VIDEO
Eduardo Parra-Davila, M.D., a robotic colorectal surgeon at Florida Hospital who has trained thousands of surgeons worldwide on robotic surgery, commented, “Single port surgery without robotic assistance is not easy and yet it remains highly beneficial because of the desire to have fewer ports. It’s all about robotic articulation delivered through a single incision that allows for the reach, necessary angles and multi-quadrant access to treat diseases in colorectal surgeries. The SPORT Surgical System has the promise to become a valuable tool for all robotic surgeons looking to do single port surgery in the future.” SEE VIDEO
Arnold Advincula, M.D., Chief of Gynecologic Specialty Surgery at Columbia University and an expert in robotic surgery, said, “After using the SPORT system, I am more convinced that single-port robotic surgery could become a reality for many patients. Previous approaches to single-incision surgery have been limiting and ineffective. The SPORT system demonstrated that it can not only address those limitations, but it may also provide some unique capabilities for enabling a variety of gynecologic surgeries through a single incision. The future of single-port robotic surgery is bright and I am excited to actively participate in this journey with Titan Medical.”
Vipul Patel, M.D., a world-renowned robotic urology surgeon from the Global Robotics Institute at Florida Hospital and the only surgeon in the world to have completed 10,000 robotic prostatectomies, said, “Although multi-port robotic prostatectomy is currently the standard of care in urology, single port robotic surgery could be the next frontier in urology and other surgical disciplines. It was exciting for me to use Titan Medical’s SPORT system at Florida Hospital Nicholson Center. The technological capabilities of the SPORT system are very encouraging and the early success in establishing feasibility is an important step in the right direction.”
William Burke, M.D., a gynecologic oncologist at Stony Brook University Hospital with extensive robotic surgery experience, commented, “Having completed thousands of multi-port robotic surgeries over several years of practice, I was pleased with the capabilities of the SPORT system that eased my transition from a multi-port approach to single-port robotic surgery. The workspace, access and ease of use while maintaining critical multi-port robotic features such as multi-articulated instruments and high-definition 3D visualization through a single incision, are important factors in transitioning from multi-port to single-port robotic surgery. I must say that the SPORT system, with its sophistication, makes a highly compelling case for single-port robotic surgery.”
Lee Swanstrom, MD, FACS, Chief Innovation Officer of IHU Strasbourg, said, “I was pleased with my first experience with the SPORT system for applications in abdominal procedures. There are many patients undergoing general surgical procedures who could greatly benefit from a reduced number of incisions. Single-port robotic surgery can be a truly enabling solution for patients and surgeons alike, and it is exciting to see that the SPORT system takes us much closer to that possibility.”
Jelle Ruurda, MD, a gastrointestinal and oncologic surgeon at University Medical Center Utrecht, who has several years of robotic surgery experience, commented, “Many oncologic general surgery procedures require specimen retrieval at the end of the procedure. These procedures are natural applications for single-port robotic surgery. My first operation of the SPORT system in a preclinical environment was very exciting, and the system shows great promise for future clinical use. I look forward to the opportunity to work together with Titan Medical to evolve a single-port robotic surgery option for my oncology patients. Based on this first experience, I am confident that single-port robotic surgery has a bright future”.
Eric Barret, MD, a world-renowned robotic urologic surgeon at Institut Mutualiste Montsouris, said, “Having performed many single-incision robotic surgeries with flexible, non-wristed and crossed-over instruments, my first experience with the SPORT system was exceptional. The SPORT system addresses many limitations of previous laparoscopic and robotic single-incision surgery approaches, and holds significant promise for meaningful use in urologic applications.”
The SPORT Surgical System is a versatile single incision advanced robotic surgical system that features state-of the-art multi-articulated instruments with single-use replaceable tips, 3D high definition visualization on a flat-screen monitor, ergonomic open workstation and a single-arm mobile patient cart for ease of set up while enabling broad applications of single and multi-quadrant surgeries previously not possible with current robotic solutions.
Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, that trades on the Toronto Stock Exchange (TMD) and the OTCQX in the United States (TITXF). Titan is developing the SPORT™ (Single Port Orifice Robotic Technology) Surgical System for use in minimally invasive surgery (“MIS”) that is expected to be commercially available in 2019. Titan’s robotic surgical system is being designed to expand robotic surgery into areas that are currently underserviced. This will allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. Currently, the most common medical procedures for which robotic systems are used are hysterectomies and prostatectomies. Titan plans to expand the scope and obtain approval for various surgical procedures as outlined in their Corporate Presentation. http://www.titanmedicalinc.com/
Interim President & CEO
In his over 10 years at Zephyr, Mr. Cataford was able to grow the team to over 65 people, clear class II medical devices through both 510 (k) and De Novo FDA approval paths and build a 13485: 2016 certified manufacturing facility. Zephyr successfully closed on two joint ventures with established dental technology companies raising over $20 million from a combination of strategic and private investors. He brings significant high technology and medical device company experience and is a key contributor to strategy, M&A, corporate finance, governance, team building and empowerment and scale. Over the last 25 years, Mr. Cataford has also served as independent corporate director on a number of TSX, TSXV and NASDAQ company boards including: Sierra Wireless, Inc., Trakopolis IoT Corp., SemiBioSys Genetics Inc., and AGJunction Inc. Mr. Cataford has a Bachelor of Science degree in Mechanical Engineering from Queen’s University, an MBA specializing in Finance and International Strategy from Schulich School of Business at York University, and is a graduate of the Institute of Corporate Directors – Directors College, Rotman School of Business at the University of Toronto.
Dr. Advincula is Vice-Chair of Women’s Health & Chief of Gynecology at the Sloane Hospital for Women, Columbia University Medical Center/New York Presbyterian Hospital. Formerly, he was Professor of Obstetrics and Gynecology, Director of the Minimally Invasive Surgery Division and Fellowship, and Director of the Endometriosis Center at the University of Michigan. More recently, he was Director of the Center for Specialized Gynecology and Director of the Education Institute at the Nicholson Center, an advanced medical and surgical simulation training facility at Florida Health. He is currently Vice President of the American Association of Gynecologic Laparoscopy and a Member-at-Large for the Society of Gynecologic Surgeons. He is a leader in minimally invasive surgical techniques and one of the world’s most experienced gynecologic robotic surgeons, who has published and taught extensively in the area of minimally invasive surgery, as well as developed surgical instruments that are in use worldwide.
Dr. Juliane Bingener is Professor of Surgery, Mayo Clinic College of Medicine, and Vice Chair for Quality, Safety and Service in the Mayo Clinic Department of Surgery. She has a joint appointment in the Division of Gastroenterology and Hepatology, which supports her clinical interests in minimally invasive surgery, endoscopy, and gastrointestinal disease. Her research focuses on patient reported outcomes and novel technology in the diagnosis and treatment of these diseases. Dr. Bingener’s previous work included the development of a Natural Orifice Translumenal Endoscopic Surgery (NOTES) technique for using an omental patch to close perforated ulcers. Her ongoing interests focus on the development, study, and implementation of innovative endoscopic and laparoscopic approaches for gastrointestinal diseases.
Dr. Boyd is a Professor of Surgery and Director of Robotics and Biosurgery at the University of California Davis. He is Head of Adult Cardiac Surgery and Surgical Director of the Transcatheter Valve Program. He is recognized for his pioneering work in cardiothoracic surgery and for his use of robotic-assisted surgical systems. He specializes in minimally invasive cardiac and robotic-assisted heart surgery. Dr. Boyd completed the world’s first closed-chest, beating-heart coronary artery bypass surgery using a robotic system in 1999. Prior to his appointment as a professor of surgery at UC Davis Health System, Dr. Boyd served as chair of the Department of Cardiothoracic Surgery at the Cleveland Clinic in Florida. As the author of more than 70 peer-reviewed, journal articles, Dr. Boyd’s research interests include cardiac tissue regeneration using extracellular matrix/stem cells, new techniques for robot-assisted minimally invasive coronary artery revascularization, valve surgery and tele-surgery. He is a graduate of Carleton University in Ottawa, Canada and obtained his medical degree from the University of Ottawa, Canada.
Dr. Litwin trained in General Surgery at the University of Saskatchewan, and completed a hepatobiliary fellowship at the University of Toronto. He was an early pioneer in laparoscopic surgery, having performed the first laparoscopic cholecystectomy in Western Canada in 1990 and the first laparoscopic colectomy in Canada in 1991. He was a leader in educating a large number of surgeons across Canada in basic and advanced laparoscopic techniques. During the early advent of minimally invasive surgery, he innovated new laparoscopic approaches to the spine and aorta, and he participated in the development of HandPortTM, a hand assist device for laparoscopic surgery. In 1993, Dr. Litwin became the Director of Minimally Invasive Surgery at the University of Toronto. In 1997, he moved to the University of Massachusetts as Chief of Minimally Invasive Surgery. Since 2004, he has been Chairman of Surgery at the University of Massachusetts Medical School and UMass Memorial Medical Center, one of the largest Academic Health Sciences Centers in Massachusetts. There, he continues to practice minimally invasive surgery of the abdomen in addition to his administrative role.
Dr. Swanstrom heads the Division of GI and Minimally Invasive Surgery at the Oregon Clinic and is Director of the Providence Health System’s Complex GI and Foregut Surgery Postgraduate Fellowship Program. In addition, he is Clinical Professor in the Department of Surgery at OHSU, a Director of the American Board of Surgery, and Past President of both the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) and the Fellowship Council (FC). Most recently, he became the Chief Innovations Officer and Director of the Innovations Fellowship at the Institutes des Hôpitalo Universitaires of the University of Strasbourg, France. He is the editor of Surgical Innovation and the author of over 300 scientific papers and 50 book chapters. This has resulted in 13 patents and a successful medical device startup company. He is and has been an investigator on numerous outcomes research studies for new procedures such as Natural Orifice Translumenal Endoscopic Surgery (NOTES) to determine their safety and efficacy for establishing new standards of care. He remains focused on developing innovative approaches to the minimally invasive treatment of foregut and other gastrointestinal disorders.
Dr. Valvo, a practicing surgeon, is the Executive Director of Robotic and Minimally Invasive Surgery at Rochester General Hospital in Rochester, New York, where he formerly was the Chief of Urology. Following a 20-year career performing open surgery, Dr. Valvo founded the robotic surgery program at Rochester General Hospital in early 2004, which currently ranks in the top two percent of robotic surgery volume in the United States. The program has trained over 30 robotic surgeons and enabled the completion of more than 7,000 robotic urology, gynecology, general and colorectal surgeries to date. Dr. Valvo has authored more than 100 scientific articles and helped start many robotic programs in the northeast. His focus on robotic surgery credentialing led to a notable published paper on policy guidelines for robotic surgery. He is a fellow of the American College of Surgeons and American Urological Association, and a member of the Society for Laparoscopic Surgeons.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |